ArticleThe British journal of dermatology2022

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

K B Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.